Hyaluronidase Assisted Subcutaneous Infusion

PHASE3CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

March 28, 2024

Primary Completion Date

May 5, 2024

Study Completion Date

August 10, 2024

Conditions
Healthy
Interventions
DRUG

hyaluronidase

150 IU group D1:150 IU hyaluronidase+500 ml Lactated Ringer's (LR)(Subject's left or right leg); D2:150 IU hyaluronidase+250 ml Lactated Ringe's (LR)(Subject's left or right arm); D3:150 IU hyaluronidase+500 ml Normal Saline (NS)(subject's left or right leg); D4:150 IU hyaluronidase+1000 ml Lactated Ringer's (LR)(Subject's back); 385 IU group D1:385 IU hyaluronidase+250 ml Lactated Ringer's (LR)(Subject's left or right arm); 1500 IU group D1:1500 IU hyaluronidase+250 ml Lactated Ringer's (LR)(Subject's left or right arm).

DRUG

Placebo

150 IU group D1:Placebo+500 ml Lactated Ringer's (LR)(Subject's left or right leg); D2:Placeboe+250 ml Lactated Ringer's (LR)(Subject's left or right arm); D3:Placebo+500 ml Normal Saline (NS)(Subject's left or right leg); 385 IU group D1:Placebo+250 ml Lactated Ringer's (LR)(Subject's left or right arm); 1500 IU group D1:Placebo+250 ml Lactated Ringe's (LR)(Subject's left or right arm).

Trial Locations (1)

215000

Suzhou Municipal Hospital, Suzhou

All Listed Sponsors
lead

Shanghai Bao Pharmaceuticals Co., Ltd.

INDUSTRY

NCT06604546 - Hyaluronidase Assisted Subcutaneous Infusion | Biotech Hunter | Biotech Hunter